Mevo, a Brazilian digital-prescription platform, announced a BRL 95 million Series B extension on 25 March 2026, led by Prosus with Matrix Partners and Jefferson River Capital, among others. It matters because it shows how a prescriber network becomes a medicine sales channel, and because the extension was priced above the 2024 round (Brazil Journal).
The transaction
- Company. Mevo, run by co-founder Pedro Dias. It issues digital prescriptions and, from them, connects the patient with partner pharmacies and with Mevo Farma through Mevo Shop; it also deploys digital prescriptions in the public health system (SUS).
- Instrument and amount. Series B extension of BRL 95 million. The original Series B was BRL 110 million, led by Matrix Partners in September 2024, followed by a first extension from Prosus in 2024 (Brazil Journal). Cumulative: BRL 340 million across eight rounds.
- Valuation. Not disclosed; Brazil Journal reports the extension was set above the 2024 price.
- Investors. Prosus as lead, now a principal investor alongside Matrix Partners; Jefferson River Capital, Lyrical Partners, Floating Point and Verônica Serra.
- Use of proceeds. Around 100 hires and acceleration of the different verticals. The company expects a Series C of around USD 40 million within 18 months.
- Prior transaction. Acquisition of Receita Digital in April 2025, price undisclosed, which doubled the doctor base.
Value drivers
Prescriber network. 100,000 active doctors, about 15% of practising professionals in Brazil, and presence in around 1,100 hospital units, with clients such as Rede D’Or, Hospital Sírio-Libanês and Beneficência Portuguesa (Startupz). In our reading, the network is the barrier to entry: it is bought, as with Receita Digital, or built over years.
Prescription volume. 35 million prescriptions in 2025 and 50 million expected in 2026. Each prescription is a purchase decision point.
Monetisation at the pharmacy. Mevo Shop is the main source of revenue: 1,600 connected pharmacy points and 20 pharmaceutical laboratories on board, with 40 in negotiation (Brazil Journal). The prescription software is the door; the marketplace is the business.
Public sector as scale. 1.4 million SUS patients and 130 municipal health secretariats: volume and regulatory legitimacy, in our reading, more than margin.
An investor with distribution. Prosus controls iFood. A sponsor with consumer and logistics assets in the same country is, in our reading, a lead investor with strategic as well as financial optionality.
What the market is signalling
For a Mexican founder of clinical tools, the lesson is one of business model: an electronic prescription alone pays little; value appears when the doctor network connects to pharmacies and laboratories, and when the company can show conversion from prescription to purchase. Mevo’s rounds also show that an extension led by an existing investor, priced above the previous round, is a valid way to fund growth without opening a full process.
For buyers in Mexico, pharmacy chains, insurers and hospital groups, a prescriber network with auditable volume is a distribution asset comparable to the one Mevo built by acquisition. For a lender, marketplace revenue is transactional and dependent on laboratories, so debt would only make sense against multi-year contracts with the pharmaceutical industry.
G2’s reading for a mandate
In a round extension, preparation focuses on justifying the price to existing investors with figures that have changed since the previous round: prescriptions issued, pharmacies connected, laboratories on board and revenue per prescription. If the company plans a Series C within 18 months, the extension must leave the cap table and investor rights tidy for a competitive process with new funds. In Mexico, the figure an investment committee will ask for first is prescription-to-purchase conversion.
Sources
- Brazil Journal (25 March 2026): Mevo levanta R$ 95 milhões para escalar a receita digital
- Startupz (29 March 2026): Mevo capta R$ 95 milhões em extensão de Série B liderada pela Prosus